In patients with early- and late-stage CD25+ CTCL, a recombinant fusion protein targeting IL-2R had a significant and durable effect on overall response rate and progression-free survival [44]. This evidence concerns the gene IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma.